The Myotonic Dystrophy Clinical Research Network (DMCRN) sites are currently conducting a critically-important research study designed to help drug developers successfully design clinical trials and understand how to assess the efficacy of potential therapies.

We are thrilled to announce the upcoming launch in April of four grant programs aimed at accelerating research efforts to improve the lives of individuals affected by myotonic dystrophy and pave the way toward finding effective treatments and ultimately a cure for this challenging condition. There are multiple fantastic opportunities available - learn more below & get ready to apply!

Dr. Johanna Hamel, an Assistant Professor in Neurology, Pathology, and Laboratory Medicine, developed her interest in DM1 and DM2 during medical school in Germany. Her residency at the University of Rochester, chosen for its focus on neuromuscular medicine and DM, led to a fellowship under Dr. Charles Thornton, funded by the Clinical Research Training Fellowship Award in Muscular Dystrophy.

Leading up to and after the 2024 MDF Regional Conferences in the spring, our biotechnology and pharmaceutical partners, large and small, working on treatments and a cure for myotonic dystrophy will sit down with our community to share their progress and answer your questions in real time.